Skin cancers are cancers that arise from the skin. They are due to the development of abnormal cells that have the ability to invade or spread to other parts of the body. There are three main types of skin cancers: basal-cell skin cancer (BCC), squamous-cell skin cancer (SCC) and melanoma. The first two, along with a number of less common skin cancers, are known as nonmelanoma skin cancer (NMSC). Basal-cell cancer grows slowly and can damage the tissue around it but is unlikely to spread to distant areas or result in death. It often appears as a painless raised area of skin that may be shiny with small blood vessels running over it or may present as a raised area with an ulcer. Squamous-cell skin cancer is more likely to spread. It usually presents as a hard lump with a scaly top but may also form an ulcer. Melanomas are the most aggressive. Signs include a mole that has changed in size, shape, color, has irregular edges, has more than one color, is itchy or bleeds.
Immunotherapy or biological therapy is the treatment of disease by activating or suppressing the immune system. Immunotherapies designed to elicit or amplify an immune response are classified as activation immunotherapies, while immunotherapies that reduce or suppress are classified as suppression immunotherapies.
Melanoma, also redundantly known as malignant melanoma, is a type of skin cancer that develops from the pigment-producing cells known as melanocytes. Melanomas typically occur in the skin, but may rarely occur in the mouth, intestines, or eye. In women, they most commonly occur on the legs, while in men, they most commonly occur on the back. About 25% of melanomas develop from moles. Changes in a mole that can indicate melanoma include an increase in size, irregular edges, change in color, itchiness, or skin breakdown.
The impact factor (IF) or journal impact factor (JIF) of an academic journal is a scientometric index calculated by Clarivate that reflects the yearly mean number of citations of articles published in the last two years in a given journal, as indexed by Clarivate's Web of Science. As a journal-level metric, it is frequently used as a proxy for the relative importance of a journal within its field; journals with higher impact factor values are given status of being more important, or carry more prestige in their respective fields, than those with lower values. While frequently used by universities and funding bodies to decide on promotion and research proposals, it has recently come under attack for distorting good scientific practices.
Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines. Released in beta in November 2004, the Google Scholar index includes most peer-reviewed online academic journals and books, conference papers, theses and dissertations, preprints, abstracts, technical reports, and other scholarly literature, including court opinions and patents. Google Scholar uses a web crawler, or web robot, to identify files for inclusion in the search results. For content to be indexed in Google Scholar, it must meet certain specified criteria. An earlier statistical estimate published in PLOS One using a Mark and recapture method estimated approximately 80–90% coverage of all articles published in English with an estimate of 100 million. This estimate also determined how many documents were freely available on the internet.
Accounts of Chemical Research is a monthly peer-reviewed scientific journal published by the American Chemical Society containing overviews of basic research and applications in chemistry and biochemistry. It was established in 1968 and the editor-in-chief is Cynthia J. Burrows.
Microphthalmia-associated transcription factor also known as class E basic helix-loop-helix protein 32 or bHLHe32 is a protein that in humans is encoded by the MITF gene.
Ipilimumab, sold under the brand name Yervoy, is a monoclonal antibody medication that works to activate the immune system by targeting CTLA-4, a protein receptor that downregulates the immune system.
The Journal of Sex Research is a peer-reviewed academic journal covering the study of human sexuality and the field of sexology in general. It is published by Routledge on behalf of the Society for the Scientific Study of Sexuality. In 1963, the society had published a one-issue journal entitled Advances in Sex Research. The Journal of Sex Research was then first published in 1965. The current editor-in-chief is Cynthia A. Graham.
Current Biology is a biweekly peer-reviewed scientific journal that covers all areas of biology, especially molecular biology, cell biology, genetics, neurobiology, ecology, and evolutionary biology. The journal includes research articles, various types of review articles, as well as an editorial magazine section. The journal was established in 1991 by the Current Science group, acquired by Elsevier in 1998 and has since 2001 been part of Cell Press, a subdivision of Elsevier. According to Journal Citation Reports, the journal has a 2020 impact factor of 10.834. It was categorized as a "high impact journal" by the Superfund Research Program.
Oral pigmentation is asymptomatic and does not usually cause any alteration to the texture or thickness of the affected area. The colour can be uniform or speckled and can appear solitary or as multiple lesions. Depending on the site, depth, and quantity of pigment, the appearance can vary considerably.
Mutation Research is a peer-reviewed scientific journal that publishes research papers in the area of mutation research which focus on fundamental mechanisms underlying the phenotypic and genotypic expression of genetic damage. There are currently three sections:
Pigment Cell & Melanoma Research is a peer-reviewed scientific journal of dermatology. It is the official journal of the International Federation of Pigment Cell Societies (IFPCS) and the Society for Melanoma Research (SMR). In 2014, it ranked the 3rd most cited journal of dermatology, out of 62.
The Journal of Clinical Psychopharmacology is a peer-reviewed medical journal published by Lippincott Williams & Wilkins covering clinical psychopharmacology. It was founded by Richard I. Shader, MD in 1981 as the first journal of an international scope devoted solely to clinical psychopharmacology. David J. Greenblatt, MD served as Co-Editor-In-Chief. Drs. Shader and Greenblatt remained at the helm of the journal until both retired at the end of 2020. Anthony J. Rothschild, MD became JCP's new Editor-in-Chief in January 2021.
Gopal Chandra Kundu is an renowned Indian cell and cancer biologist and a Senior Scientist (Scientist-G) at National Centre for Cell Science. He is known for his contributions towards the understanding the mechanism of cancer progression in breast, melanoma and other cancers and development of novel therapeutic targets and target-based therapy in cancers.
Pembrolizumab, sold under the brand name Keytruda, is a humanized antibody used in cancer immunotherapy that treats melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, stomach cancer, cervical cancer, and certain types of breast cancer. It is given by slow injection into a vein.
The immune cycle is a natural homeostatic oscillation of the immune system when chronic inflammation is occurring. Similar to the menstrual cycle, the exact wavelength and waveform of each particular individual patient is different. That is, different people have different immune cycles although each cycle is typically repeated every seven days.
J. William Harbour, M.D., is an American ophthalmologist, ocular oncologist and cancer researcher. He is currently Chair of the Department of Ophthalmology at the University of Texas Southwestern Medical Center in Dallas. He previously served as the Vice Chair and Director of Ocular Oncology at the Bascom Palmer Eye Institute and the Associate Director for Basic Science at the Sylvester Comprehensive Cancer Center of the University of Miami Miller School of Medicine. His clinical practice focuses on intraocular tumors, including uveal (ocular) melanoma, retinoblastoma, lymphoma and other neoplasms. His field of research includes the genetics and genomics of cancer, with a focus on prognostic biomarkers, mechanisms of metastasis, and molecular targeted therapies. He has given over 300 invited scientific lectures, and published over 200 peer-reviewed scientific articles and book chapters. Dr. Harbour founded the Ocular Oncology Service at the Washington University School of Medicine in St. Louis, where he was the Paul A. Cibis Distinguished Professor of Ophthalmology & Visual Sciences.
Georgina Venetia Long is Co-Medical Director of Melanoma Institute Australia (MIA), and Chair of Melanoma Medical Oncology and Translational Research at MIA and Royal North Shore Hospital, The University of Sydney.
Clarivate is a public analytics company that operates a collection of subscription-based services, in the areas of bibliometrics and scientometrics; business / market intelligence, and competitive profiling for pharmacy and biotech, patents, and regulatory compliance; trademark protection, and domain and brand protection. In the academy and the scientific community, Clarivate is known for being the company which calculates the impact factor, using data from its Web of Science product family, that also includes services/applications such as Publons, EndNote, EndNote Click, and ScholarOne. Its other product families are Cortellis, DRG, CPA Global, Derwent, MarkMonitor, CompuMark, and Darts-ip, and also the various ProQuest products and services.
